-
1
-
-
84921927301
-
Ammonia metabolism and hyperammonemic disorders
-
Walker V. Ammonia metabolism and hyperammonemic disorders. Adv Clin Chem. 2014; 67:73-150.
-
(2014)
Adv Clin Chem
, vol.67
, pp. 73-150
-
-
Walker, V.1
-
2
-
-
84896734003
-
Drug-induced removal of nitrogen derivatives in urine: a new concept whose time has come
-
Cordoba J, Ventura-Cots M. Drug-induced removal of nitrogen derivatives in urine: a new concept whose time has come. Hepatology. 2014; 59:764-766.
-
(2014)
Hepatology
, vol.59
, pp. 764-766
-
-
Cordoba, J.1
Ventura-Cots, M.2
-
4
-
-
0034885248
-
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies
-
Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res. 2001; 7:2292-2300.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 2292-2300
-
-
Gilbert, J.1
Baker, S.D.2
Bowling, M.K.3
Grochow, L.4
Figg, W.D.5
Zabelina, Y.6
Donehower, R.C.7
Carducci, M.A.8
-
5
-
-
0030861882
-
Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells
-
Gore SD, Samid D, Weng LJ. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res. 1997; 3:1755-1762.
-
(1997)
Clin Cancer Res
, vol.3
, pp. 1755-1762
-
-
Gore, S.D.1
Samid, D.2
Weng, L.J.3
-
6
-
-
0033952555
-
Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents
-
Witzig TE, Timm M, Stenson M, Svingen PA, Kaufmann SH. Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin Cancer Res. 2000; 6:681-692.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 681-692
-
-
Witzig, T.E.1
Timm, M.2
Stenson, M.3
Svingen, P.A.4
Kaufmann, S.H.5
-
7
-
-
33745714230
-
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
-
Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek, MA, Zhao M, Smith BD, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006; 66:6361-6369.
-
(2006)
Cancer Res
, vol.66
, pp. 6361-6369
-
-
Gore, S.D.1
Baylin, S.2
Sugar, E.3
Carraway, H.4
Miller, C.B.5
Carducci, M.6
Grever, M.7
Galm, O.8
Dauses, T.9
Karp, J.E.10
Rudek, M.A.11
Zhao, M.12
Smith, B.D.13
-
8
-
-
31444438952
-
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome
-
Maslak P, Chanel S, Camacho LH, Soignet S, PandolfiPP, Guernah I, Warrell R, Nimer S. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia. 2006; 20:212-217.
-
(2006)
Leukemia
, vol.20
, pp. 212-217
-
-
Maslak, P.1
Chanel, S.2
Camacho, L.H.3
Soignet, S.4
Pandolfi, P.P.5
Guernah, I.6
Warrell, R.7
Nimer, S.8
-
9
-
-
33845898832
-
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors
-
Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs. 2007; 25:131-138.
-
(2007)
Invest New Drugs
, vol.25
, pp. 131-138
-
-
Camacho, L.H.1
Olson, J.2
Tong, W.P.3
Young, C.W.4
Spriggs, D.R.5
Malkin, M.G.6
-
10
-
-
33749029926
-
Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer
-
Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res. 2006; 12:5199-5206.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 5199-5206
-
-
Kulp, S.K.1
Chen, C.S.2
Wang, D.S.3
Chen, C.Y.4
Chen, C.S.5
-
11
-
-
84923197584
-
Current treatment of early breast cancer: adjuvant and neoadjuvant therapy
-
Miller E, Lee HJ, Lulla A, Hernandez L, Gokare P, Lim B. Current treatment of early breast cancer: adjuvant and neoadjuvant therapy. F1000Res. 2014; 3:198.
-
(2014)
F1000Res
, vol.3
, pp. 198
-
-
Miller, E.1
Lee, H.J.2
Lulla, A.3
Hernandez, L.4
Gokare, P.5
Lim, B.6
-
12
-
-
84876690436
-
Breast cancer screening and the changing population pyramid of Japan
-
Uchida K, Ohashi H, Kinoshita S, Nogi H, Kato K, Toriumi Y, Yamashita A, Kamio M, Mimoto R, Takeyama H. Breast cancer screening and the changing population pyramid of Japan. Breast Cancer. 2013; 22:172-176.
-
(2013)
Breast Cancer
, vol.22
, pp. 172-176
-
-
Uchida, K.1
Ohashi, H.2
Kinoshita, S.3
Nogi, H.4
Kato, K.5
Toriumi, Y.6
Yamashita, A.7
Kamio, M.8
Mimoto, R.9
Takeyama, H.10
-
13
-
-
0028819734
-
Anthracycline resistance in breast cancer: clinical applications of current knowledge
-
Ravdin PM. Anthracycline resistance in breast cancer: clinical applications of current knowledge. Eur J Cancer. 1995; 31A Suppl 7:S11-14.
-
(1995)
Eur J Cancer
, vol.31A
, pp. S11-S14
-
-
Ravdin, P.M.1
-
14
-
-
0036237738
-
Anti-aromatase agents in the treatment and prevention of breast cancer
-
Goss P. Anti-aromatase agents in the treatment and prevention of breast cancer. Cancer Control. 2002; 9:2-8.
-
(2002)
Cancer Control
, vol.9
, pp. 2-8
-
-
Goss, P.1
-
15
-
-
33745864289
-
Biomarkers and multiple drug resistance in breast cancer
-
O'Driscoll L, Clynes M. Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets. 2006; 6:365-384.
-
(2006)
Curr Cancer Drug Targets
, vol.6
, pp. 365-384
-
-
O'Driscoll, L.1
Clynes, M.2
-
16
-
-
84896501972
-
In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells
-
Tahmasebi F, Kazemi T, Amiri MM, Khoshnoodi J, Mahmoudian J, Bayat AA, Jeddi-Tehrani M, Rabbani H, Shokri F. In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells. Immunotherapy. 2012; 6:43-49.
-
(2012)
Immunotherapy
, vol.6
, pp. 43-49
-
-
Tahmasebi, F.1
Kazemi, T.2
Amiri, M.M.3
Khoshnoodi, J.4
Mahmoudian, J.5
Bayat, A.A.6
Jeddi-Tehrani, M.7
Rabbani, H.8
Shokri, F.9
-
17
-
-
23844501979
-
Adjuvant trastuzumab for HER2-positive breast cancer
-
Spicer J, Harries M, Ellis P. Adjuvant trastuzumab for HER2-positive breast cancer. Lancet. 2005; 366:634.
-
(2005)
Lancet
, vol.366
, pp. 634
-
-
Spicer, J.1
Harries, M.2
Ellis, P.3
-
18
-
-
58149252473
-
Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer
-
Scurr LL, Guminski AD, Chiew YE, Balleine RL, Sharma R, Lei Y, Pryor K, Wain GV, Brand A, Byth K, Kennedy C, Rizos H, Harnett PR, et al. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer. Clin Cancer Res. 2008; 14:6924-6932.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6924-6932
-
-
Scurr, L.L.1
Guminski, A.D.2
Chiew, Y.E.3
Balleine, R.L.4
Sharma, R.5
Lei, Y.6
Pryor, K.7
Wain, G.V.8
Brand, A.9
Byth, K.10
Kennedy, C.11
Rizos, H.12
Harnett, P.R.13
-
19
-
-
84880922644
-
Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer
-
Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH, Lu X, Baron AE, Franklin WA, Merrick DT, Jedlicka P, DeRyckere D, Heasley LE, et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene. 2012; 32:3420-3431.
-
(2012)
Oncogene
, vol.32
, pp. 3420-3431
-
-
Linger, R.M.1
Cohen, R.A.2
Cummings, C.T.3
Sather, S.4
Migdall-Wilson, J.5
Middleton, D.H.6
Lu, X.7
Baron, A.E.8
Franklin, W.A.9
Merrick, D.T.10
Jedlicka, P.11
DeRyckere, D.12
Heasley, L.E.13
-
20
-
-
21344437105
-
Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma
-
Nakatani K, Wada T, Nakamura M, Uzawa K, Tanzawa H, Fujita S. Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2005; 131:445-452.
-
(2005)
J Cancer Res Clin Oncol
, vol.131
, pp. 445-452
-
-
Nakatani, K.1
Wada, T.2
Nakamura, M.3
Uzawa, K.4
Tanzawa, H.5
Fujita, S.6
-
21
-
-
84872617436
-
WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells
-
Yuan G, Regel I, Lian F, Friedrich T, Hitkova I, Hofheinz RD, Strobel P, Langer R, Keller G, Rocken C, Zimmermann W, Schmid RM. Ebert MP, et al. WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells. Oncogene. 2013; 32:375-387.
-
(2013)
Oncogene
, vol.32
, pp. 375-387
-
-
Yuan, G.1
Regel, I.2
Lian, F.3
Friedrich, T.4
Hitkova, I.5
Hofheinz, R.D.6
Strobel, P.7
Langer, R.8
Keller, G.9
Rocken, C.10
Zimmermann, W.11
Schmid, R.M.12
Ebert, M.P.13
-
22
-
-
84869208957
-
An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer
-
McCleland ML, Adler AS, Shang Y, Hunsaker T, Truong T, Peterson D, Torres E, Li L, Haley B, Stephan JP, Belvin M, Hatzivassiliou G, Blackwood EM, et al. An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res. 2012; 72:5812-5823.
-
(2012)
Cancer Res
, vol.72
, pp. 5812-5823
-
-
McCleland, M.L.1
Adler, A.S.2
Shang, Y.3
Hunsaker, T.4
Truong, T.5
Peterson, D.6
Torres, E.7
Li, L.8
Haley, B.9
Stephan, J.P.10
Belvin, M.11
Hatzivassiliou, G.12
Blackwood, E.M.13
-
23
-
-
77956448047
-
Drug resistant breast cancer cells overexpress ETS1 gene
-
Kars MD, Iseri OD, Gunduz U. Drug resistant breast cancer cells overexpress ETS1 gene. Biomed Pharmacother. 2010; 64:458-462.
-
(2010)
Biomed Pharmacother
, vol.64
, pp. 458-462
-
-
Kars, M.D.1
Iseri, O.D.2
Gunduz, U.3
-
25
-
-
84896537393
-
Differential regulation of estrogen receptor alpha expression in breast cancer cells by metastasis-associated protein 1
-
Kang HJ, Lee MH, Kang HL, Kim SH, Ahn JR, Na H, Na TY, Kim YN, Seong JK, Lee MO. Differential regulation of estrogen receptor alpha expression in breast cancer cells by metastasis-associated protein 1. Cancer Res. 2014; 74:1484-1494.
-
(2014)
Cancer Res
, vol.74
, pp. 1484-1494
-
-
Kang, H.J.1
Lee, M.H.2
Kang, H.L.3
Kim, S.H.4
Ahn, J.R.5
Na, H.6
Na, T.Y.7
Kim, Y.N.8
Seong, J.K.9
Lee, M.O.10
-
26
-
-
84873371589
-
PTRF/cavin-1 is essential for multidrug resistance in cancer cells
-
Yi JS, Mun DG, Lee H, Park JS, Lee JW, Lee JS, Kim SJ, Cho BR, Lee SW, Ko YG. PTRF/cavin-1 is essential for multidrug resistance in cancer cells. J Proteome Res. 2013; 12:605-614.
-
(2013)
J Proteome Res
, vol.12
, pp. 605-614
-
-
Yi, J.S.1
Mun, D.G.2
Lee, H.3
Park, J.S.4
Lee, J.W.5
Lee, J.S.6
Kim, S.J.7
Cho, B.R.8
Lee, S.W.9
Ko, Y.G.10
-
27
-
-
84866075905
-
Transcriptional and epigenetic regulation of KIAA1199 gene expression in human breast cancer
-
Kuscu C, Evensen N, Kim D, Hu YJ, Zucker S, Cao J. Transcriptional and epigenetic regulation of KIAA1199 gene expression in human breast cancer. PLoS One. 2012; 7:e44661.
-
(2012)
PLoS One
, vol.7
-
-
Kuscu, C.1
Evensen, N.2
Kim, D.3
Hu, Y.J.4
Zucker, S.5
Cao, J.6
-
28
-
-
0023895229
-
Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas
-
Cattoretti G, Andreola S, Clemente C, D'Amato L, Rilke F. Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. Br J Cancer. 1988; 57:353-357.
-
(1988)
Br J Cancer
, vol.57
, pp. 353-357
-
-
Cattoretti, G.1
Andreola, S.2
Clemente, C.3
D'Amato, L.4
Rilke, F.5
-
29
-
-
0033231071
-
Tumorigenicity of human breast cancer is associated with loss of the Ca2+-activated chloride channel CLCA2
-
Gruber AD, Pauli BU. Tumorigenicity of human breast cancer is associated with loss of the Ca2+-activated chloride channel CLCA2. Cancer Res. 1999; 59:5488-5491.
-
(1999)
Cancer Res
, vol.59
, pp. 5488-5491
-
-
Gruber, A.D.1
Pauli, B.U.2
-
30
-
-
84860304606
-
Loss of breast epithelial marker hCLCA2 promotes epithelialto-mesenchymal transition and indicates higher risk of metastasis
-
Walia V, Yu Y, Cao D, Sun M, McLean JR, Hollier BG, Cheng J, Mani SA, Rao K, Premkumar L, Elble RC. Loss of breast epithelial marker hCLCA2 promotes epithelialto-mesenchymal transition and indicates higher risk of metastasis. Oncogene. 2012; 31:2237-2246.
-
(2012)
Oncogene
, vol.31
, pp. 2237-2246
-
-
Walia, V.1
Yu, Y.2
Cao, D.3
Sun, M.4
McLean, J.R.5
Hollier, B.G.6
Cheng, J.7
Mani, S.A.8
Rao, K.9
Premkumar, L.10
Elble, R.C.11
-
31
-
-
84907483753
-
Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms
-
Ishii H, Saitoh M, Sakamoto K, Kondo T, Katoh R, Tanaka S, Motizuki M, Masuyama K, Miyazawa K. Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms. J Biol Chem. 2014; 289:27386-27399.
-
(2014)
J Biol Chem
, vol.289
, pp. 27386-27399
-
-
Ishii, H.1
Saitoh, M.2
Sakamoto, K.3
Kondo, T.4
Katoh, R.5
Tanaka, S.6
Motizuki, M.7
Masuyama, K.8
Miyazawa, K.9
-
32
-
-
33747363496
-
FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer
-
Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, Ulm K, Kiechle M, Hoefler H, Ullrich A, Harbeck N. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol. 2006; 24:3747-3755.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3747-3755
-
-
Thussbas, C.1
Nahrig, J.2
Streit, S.3
Bange, J.4
Kriner, M.5
Kates, R.6
Ulm, K.7
Kiechle, M.8
Hoefler, H.9
Ullrich, A.10
Harbeck, N.11
-
33
-
-
68649115260
-
Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study
-
Valladares-Ayerbes M, Iglesias-Diaz P, Diaz-Prado S, Ayude D, Medina V, Haz M, Reboredo M, Antolin S, Calvo L, Anton-Aparicio LM. Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study. J Cancer Res Clin Oncol. 2009; 135:1185-1195.
-
(2009)
J Cancer Res Clin Oncol
, vol.135
, pp. 1185-1195
-
-
Valladares-Ayerbes, M.1
Iglesias-Diaz, P.2
Diaz-Prado, S.3
Ayude, D.4
Medina, V.5
Haz, M.6
Reboredo, M.7
Antolin, S.8
Calvo, L.9
Anton-Aparicio, L.M.10
-
34
-
-
79952318223
-
Down-regulation of FXYD3 is induced by transforming growth factor-beta signaling via ZEB1/deltaEF1 in human mammary epithelial cells
-
Yamamoto H, Mukaisho K, Sugihara H, Hattori T, Asano S. Down-regulation of FXYD3 is induced by transforming growth factor-beta signaling via ZEB1/deltaEF1 in human mammary epithelial cells. Biol Pharm Bull. 2011; 34:324-329.
-
(2011)
Biol Pharm Bull
, vol.34
, pp. 324-329
-
-
Yamamoto, H.1
Mukaisho, K.2
Sugihara, H.3
Hattori, T.4
Asano, S.5
-
35
-
-
84869228632
-
Rab25 is a tumor suppressor gene with antiangiogenic and anti-invasive activities in esophageal squamous cell carcinoma
-
Tong M, Chan KW, Bao JY, Wong KY, Chen JN, Kwan PS, Tang KH, Fu L, Qin YR, Lok S, Guan XY, Ma S. Rab25 is a tumor suppressor gene with antiangiogenic and anti-invasive activities in esophageal squamous cell carcinoma. Cancer Res. 2012; 72:6024-6035.
-
(2012)
Cancer Res
, vol.72
, pp. 6024-6035
-
-
Tong, M.1
Chan, K.W.2
Bao, J.Y.3
Wong, K.Y.4
Chen, J.N.5
Kwan, P.S.6
Tang, K.H.7
Fu, L.8
Qin, Y.R.9
Lok, S.10
Guan, X.Y.11
Ma, S.12
-
36
-
-
84894361386
-
SEPP1 influences breast cancer risk among women with greater native american ancestry: the breast cancer health disparities study
-
Pellatt AJ, WolffRK, John EM, Torres-Mejia G, Hines LM, Baumgartner KB, Giuliano AR, Lundgreen A, Slattery ML. SEPP1 influences breast cancer risk among women with greater native american ancestry: the breast cancer health disparities study. PLoS One. 2013; 8:e80554.
-
(2013)
PLoS One
, vol.8
-
-
Pellatt, A.J.1
Wolff, R.K.2
John, E.M.3
Torres-Mejia, G.4
Hines, L.M.5
Baumgartner, K.B.6
Giuliano, A.R.7
Lundgreen, A.8
Slattery, M.L.9
-
37
-
-
0032403128
-
Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways
-
Turner BC, Zhang J, Gumbs AA, Maher MG, Kaplan L, Carter D, Glazer PM, Hurst HC, Haffty BG, Williams T. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Res. 1998; 58:5466-5472.
-
(1998)
Cancer Res
, vol.58
, pp. 5466-5472
-
-
Turner, B.C.1
Zhang, J.2
Gumbs, A.A.3
Maher, M.G.4
Kaplan, L.5
Carter, D.6
Glazer, P.M.7
Hurst, H.C.8
Haffty, B.G.9
Williams, T.10
-
38
-
-
84924059687
-
TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer
-
Seksenyan A, Kadavallore A, Walts AE, de la Torre B, Berel D, Strom SP, Aliahmad P, Funari VA, Kaye J. TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer. BMC Cancer. 2015; 15:22.
-
(2015)
BMC Cancer
, vol.15
, pp. 22
-
-
Seksenyan, A.1
Kadavallore, A.2
Walts, A.E.3
de la Torre, B.4
Berel, D.5
Strom, S.P.6
Aliahmad, P.7
Funari, V.A.8
Kaye, J.9
-
39
-
-
0032948005
-
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
-
Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999; 21:103-107.
-
(1999)
Nat Genet
, vol.21
, pp. 103-107
-
-
Cameron, E.E.1
Bachman, K.E.2
Myohanen, S.3
Herman, J.G.4
Baylin, S.B.5
-
40
-
-
0037455825
-
Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells
-
Yamashita Y, Shimada M, Harimoto N, Rikimaru T, Shirabe K, Tanaka S, Sugimachi K. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer. 2003; 103:572-576.
-
(2003)
Int J Cancer
, vol.103
, pp. 572-576
-
-
Yamashita, Y.1
Shimada, M.2
Harimoto, N.3
Rikimaru, T.4
Shirabe, K.5
Tanaka, S.6
Sugimachi, K.7
-
41
-
-
0034672294
-
Effect of trichostatin A on cell growth and expression of cell cycleand apoptosis-related molecules in human gastric and oral carcinoma cell lines
-
Suzuki T, Yokozaki H, Kuniyasu H, Hayashi K, Naka K, Ono S, Ishikawa T, Tahara E, Yasui W. Effect of trichostatin A on cell growth and expression of cell cycleand apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer. 2000; 88:992-997.
-
(2000)
Int J Cancer
, vol.88
, pp. 992-997
-
-
Suzuki, T.1
Yokozaki, H.2
Kuniyasu, H.3
Hayashi, K.4
Naka, K.5
Ono, S.6
Ishikawa, T.7
Tahara, E.8
Yasui, W.9
-
42
-
-
84876432144
-
Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells
-
Roche J, Nasarre P, Gemmill R, Baldys A, Pontis J, Korch C, Guilhot J, Ait-Si-Ali S, Drabkin H. Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers (Basel). 2013; 5:334-356.
-
(2013)
Cancers (Basel)
, vol.5
, pp. 334-356
-
-
Roche, J.1
Nasarre, P.2
Gemmill, R.3
Baldys, A.4
Pontis, J.5
Korch, C.6
Guilhot, J.7
Ait-Si-Ali, S.8
Drabkin, H.9
-
43
-
-
70450198396
-
Epithelialmesenchymal transitions in development and disease
-
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009; 139:871-890.
-
(2009)
Cell
, vol.139
, pp. 871-890
-
-
Thiery, J.P.1
Acloque, H.2
Huang, R.Y.3
Nieto, M.A.4
-
44
-
-
81255168182
-
Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations
-
Floor S, van Staveren WC, Larsimont D, Dumont JE, Maenhaut C. Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene. 2011; 30:4609-4621.
-
(2011)
Oncogene
, vol.30
, pp. 4609-4621
-
-
Floor, S.1
van Staveren, W.C.2
Larsimont, D.3
Dumont, J.E.4
Maenhaut, C.5
-
45
-
-
77956230322
-
The ZEB/miR-200 feedback loop a motor of cellular plasticity in development and cancer?
-
Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop a motor of cellular plasticity in development and cancer? EMBO Rep. 2010; 11:670-677.
-
(2010)
EMBO Rep
, vol.11
, pp. 670-677
-
-
Brabletz, S.1
Brabletz, T.2
-
46
-
-
77955497665
-
The role of the miR-200 family in epithelial-mesenchymal transition
-
Mongroo PS, Rustgi AK. The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther. 2010; 10:219-222.
-
(2010)
Cancer Biol Ther
, vol.10
, pp. 219-222
-
-
Mongroo, P.S.1
Rustgi, A.K.2
-
47
-
-
73049110243
-
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs
-
Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton, J, Sansom O, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009; 11:1487-1495.
-
(2009)
Nat Cell Biol
, vol.11
, pp. 1487-1495
-
-
Wellner, U.1
Schubert, J.2
Burk, U.C.3
Schmalhofer, O.4
Zhu, F.5
Sonntag, A.6
Waldvogel, B.7
Vannier, C.8
Darling, D.9
zur Hausen, A.10
Brunton, V.G.11
Morton, J.12
Sansom, O.13
-
48
-
-
84879863078
-
Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state
-
Lim YY, Wright JA, Attema JL, Gregory PA, Bert AG, Smith E, Thomas D, Lopez AF, Drew PA, Khew-Goodall Y. Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. J Cell Sci. 2013; 126:2256-2266.
-
(2013)
J Cell Sci
, vol.126
, pp. 2256-2266
-
-
Lim, Y.Y.1
Wright, J.A.2
Attema, J.L.3
Gregory, P.A.4
Bert, A.G.5
Smith, E.6
Thomas, D.7
Lopez, A.F.8
Drew, P.A.9
Khew-Goodall, Y.10
-
49
-
-
84920156555
-
The downregulation of miR-200c/141 promotes ZEB1/2 expression and gastric cancer progression
-
Zhou X, Wang Y, Shan B, Han J, Zhu H, Lv Y, Fan X, Sang M, Liu XD, Liu W. The downregulation of miR-200c/141 promotes ZEB1/2 expression and gastric cancer progression. Med Oncol. 2015; 32:428.
-
(2015)
Med Oncol
, vol.32
, pp. 428
-
-
Zhou, X.1
Wang, Y.2
Shan, B.3
Han, J.4
Zhu, H.5
Lv, Y.6
Fan, X.7
Sang, M.8
Liu, X.D.9
Liu, W.10
-
50
-
-
77951912503
-
Tumor suppressor function of Rab25 in triple-negative breast cancer
-
Cheng JM, Volk L, Janaki DK, Vyakaranam S, Ran S, Rao KA. Tumor suppressor function of Rab25 in triple-negative breast cancer. Int J Cancer. 2010; 126:2799-2812.
-
(2010)
Int J Cancer
, vol.126
, pp. 2799-2812
-
-
Cheng, J.M.1
Volk, L.2
Janaki, D.K.3
Vyakaranam, S.4
Ran, S.5
Rao, K.A.6
-
51
-
-
84901746783
-
Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing
-
Xu Y, Gao XD, Lee JH, Huang H, Tan H, Ahn J, Reinke LM, Peter ME, Feng Y, Gius D, Siziopikou KP, Peng J, Xiao X, et al. Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing. Genes Dev. 2014; 28:1191-1203.
-
(2014)
Genes Dev
, vol.28
, pp. 1191-1203
-
-
Xu, Y.1
Gao, X.D.2
Lee, J.H.3
Huang, H.4
Tan, H.5
Ahn, J.6
Reinke, L.M.7
Peter, M.E.8
Feng, Y.9
Gius, D.10
Siziopikou, K.P.11
Peng, J.12
Xiao, X.13
-
52
-
-
84866989871
-
High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines
-
Vergara-Lluri ME, Moatamed NA, Hong E, Apple SK. High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines. Mod Pathol. 2012; 25:1326-1332.
-
(2012)
Mod Pathol
, vol.25
, pp. 1326-1332
-
-
Vergara-Lluri, M.E.1
Moatamed, N.A.2
Hong, E.3
Apple, S.K.4
|